LXEO Lexeo Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-02
Why LXEO matters now
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.69 with +5.39% on the session and $368.3M in market capitalization; recent performance reads 1-month +10.04% and YTD -50.35%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-20.2M, and EPS of $-0.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.4%.
The latest indexable market news headline is "Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Townsend Richard Nolan filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.73
P/S
0.00
EV/EBITDA
-3.79
DCF Value
$0.95
FCF Yield
-25.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.5%
ROA
-35.0%
ROIC
-40.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-20.2M | $-0.25 |
| Q4 2025 | $0.00 | $-20.9M | $-0.27 |
| FY 2025 | $0.00 | $-100.0M | $-1.86 |
| Q3 2025 | $0.00 | $-20.3M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.39
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.